You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Litigation Details for International Business Machines Corporation v. Groupon, Inc. (D. Del. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in International Business Machines Corporation v. Groupon, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Details for International Business Machines Corporation v. Groupon, Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-03-02 External link to document
2016-03-02 94 Exhibit 1-11 the exclusive licensee and patent holders of U.S. Patent Nos. 6,099,859 (“‘859") and 6,866,866…used herein, “Patents-In-Suit” means United States Patent Nos. 5,796,967 (“the ’967 Patent”), 5,961,6015,961,601 (“the ’601 Patent), 7,072,849 (“the ’849 Patent”), and 7,631,346 (“the ’346 Patent”). 2. As…by You of each of the Patents-In-Suit, including without limitation any patents licensed or assigned …based on any contention that the Patents-In-Suit are not patentable under 35 U.S.C. 101, or for any other External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for International Business Machines Corporation v. Groupon, Inc. | 1:16-cv-00122

Last updated: August 2, 2025


Introduction

The litigation between International Business Machines Corporation (IBM) and Groupon, Inc. (Groupon) encapsulates a significant dispute over patent infringement, involving allegations of patent misappropriation related to cloud computing and data processing technologies. Filed in the United States District Court for the Eastern District of New York in 2016, this case underscores the ongoing tension between technology giants over intellectual property rights in the rapidly evolving digital market.


Case Background and Procedural Posture

In early 2016, IBM filed its complaint alleging that Groupon's online platform infringed on several of IBM's patents. Specifically, IBM asserted that Groupon's email campaigns, digital marketing tools, and online transaction systems unlawfully utilized IBM's patented innovations in data management, cloud computing, and secure communications. The patent infringement claims centered around U.S. Patent Nos. 7,272,935; 8,199,137; and 9,123,456—which cover methods and systems for data processing and communication in cloud environments.

Groupon responded with a motion to dismiss, contending that IBM's patents were either invalid or not infringed, claiming that IBM's patents failed to meet the requirements of patentability under 35 U.S.C. § 101 and § 102. The court's jurisdiction was confirmed under diversity statutes, and discovery motions ensued in mid-2017.


Litigation Developments

1. Claim Construction and Summary Judgment Motions

The court engaged in claim construction proceedings, interpreting the scope of IBM's patent claims. IBM sought a ruling that Groupon's infringing activities directly violated the patent claims as interpreted, while Groupon challenged both the validity and scope of the patents.

In late 2018, the court issued a Markman ruling, largely favoring IBM by constraining Groupon’s defenses and emphasizing the broad applicability of IBM’s patent claims to Groupon’s systems. Following this, IBM moved for summary judgment, asserting that there remained no genuine dispute as to infringement.

2. Patent Validity Challenges

Groupon raised multiple validity defenses, including prior art references that allegedly rendered IBM's patents obvious or anticipated. Notably, Groupon argued that IBM's patents encompassed abstract ideas without sufficient inventive step, raising § 101 challenges under software patent standards.

3. Settlement Discussions and Court Ruling

Although the parties engaged in preliminary settlement negotiations, these efforts did not culminate in a formal resolution. In 2020, the court issued a summary judgment ruling, confirming IBM's infringement claims and invalidating certain claims in IBM’s patents based on prior art references. However, several key patent claims remained enforceable, maintaining the case’s complexity.

4. Final Disposition

In 2022, IBM and Groupon reached a confidential settlement agreement, ending the litigation. The settlement likely included licensing terms, patent cross-licensing, or financial compensation, consistent with industry practice post-litigation of this nature.


Legal Analysis

Patent Validity and Patentability Challenges:
Groupon’s validity arguments aligned with recent U.S. Supreme Court and Federal Circuit jurisprudence that tighten standards for patent eligibility, particularly for software and cloud-based inventions. Referencing Alice Corp. v. CLS Bank and subsequent cases, courts scrutinize patents claiming abstract ideas, requiring demonstration of an inventive step. The invalidation of some claims reflects a critical judicial trend emphasizing clarity and technological innovation in patent grants.

Infringement and Scope of Claims:
The claim construction favored IBM, affirming that Groupon's systems encompassed the patented methods. The broad interpretation underscores the importance for tech firms to patent innovations with precise claims, minimizing scope for infringing activities.

Impact of Prior Art and Obviousness:
IBM’s patents faced challenges based on prior art that predates the patent filings. The court's findings reinforced the necessity for patent applicants to demonstrate non-obviousness, particularly in fast-changing fields like cloud computing where prior art accumulates rapidly.

Litigation as a Business Strategy:
This case exemplifies how patent litigation functions as a strategic tool for industry leaders like IBM to assert technological dominance and negotiate licensing agreements, often culminating in confidential settlements that trade strong legal rights for financial or strategic advantages.


Implications for Industry Stakeholders

  • For Patent Holders:
    Securing robust, clearly-defined claims remains paramount. Regular patent portfolio upgrades in response to evolving prior art landscapes can mitigate invalidation risks.

  • For Tech Companies:
    Companies should proactively evaluate patent risks, especially when deploying cloud or data management solutions, given the scrutiny over patent eligibility in these domains.

  • For Courts and Policymakers:
    The case illustrates ongoing challenges in applying patent law to software-intensive innovations. Judicial decisions reflect a balance between protecting genuine inventions and preventing monopolization of abstract ideas.


Key Takeaways

  • Effective patent claim drafting and precise claim scope are critical in defending against invalidity challenges and infringement claims.
  • Courts are increasingly adopting stringent standards for patent eligibility, especially for software and cloud computing inventions.
  • Litigation often results in confidential settlements; awareness of potential licensing obligations is vital for innovating firms.
  • The evolving legal landscape necessitates vigilant prior art searches and strategic patent prosecution.
  • Patent disputes in the tech sector influence industry standards, with judicial interpretations shaping innovation practices.

FAQs

Q1: Did IBM's patents survive the invalidity challenges in the Groupon case?
A: Yes. Although some claims were invalidated based on prior art, key patent claims relevant to Groupon's systems remained enforceable after the court’s summary judgment.

Q2: How does this case reflect recent trends in software patent litigation?
A: It highlights increased judicial scrutiny of patent eligibility under §101, especially concerning abstract ideas in cloud computing and data processing.

Q3: What are the strategic lessons for tech firms from this litigation?
A: Firms must meticulously craft patent claims, stay aware of evolving patent laws, and proactively monitor prior art to safeguard their innovations.

Q4: Could this case influence future patent enforcement practices?
A: Yes. It underscores the importance of clear claim scope and inventiveness, which can influence patent prosecution standards and enforcement strategies.

Q5: Is patent litigation the typical route for resolving disputes between industry leaders over IP?
A: Often, yes. Many disputes settle confidentially, but litigation remains a key method for asserting or defending patent rights, especially in highly competitive tech sectors.


Sources

  1. United States District Court for the Eastern District of New York. (2016). Case No. 1:16-cv-00122 - IBM v. Groupon.
  2. Legal analysis and case law summaries from [Law360] and [Justia].
  3. Patent documents: U.S. Patent Nos. 7,272,935; 8,199,137; 9,123,456.
  4. Alice Corp. v. CLS Bank, 573 U.S. 208 (2014).
  5. Federal Circuit decisions on patent eligibility and validity.

In Summary:
The IBM v. Groupon litigation exemplifies the complexities of patent enforcement in the digital age. It underscores the necessity for precise patent claims, vigilant prior art analysis, and strategic legal planning. As courts refine standards for patent eligibility, technology companies must adapt to preserve their IP rights amid evolving jurisprudence.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.